Motus GI Hlds

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in 2008 and is headquartered in Fort Lauderdale, FL.

Motus GI Holdings, Inc. (NASDAQ:MOTS ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim Moran - Chief Executive Officer Andrew Taylor - Chief Financial Officer Mark Pomeranz - President and Chief Operating Officer Conference Call Participants Steven Lichtman - Oppenheimer Boobalan Pachaiyappan - H.C. Wainwright Operator Good day, and welcome to the Motus GI First Quarter 2022 Earnings Call.

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q1 2022 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Motus GI Reports First Quarter 2022 Financial Results and Provides Business Update

Motus GI Holdings, Inc. (MOTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Motus GI Holdings, Inc. (MOTS) Report Negative Earnings Next Week? What You Should Know

FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter financial results on Thursday, May 12, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release First Quarter Results and Provide a Business Update on May 12

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2021 Results - Earnings Call Transcript

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0% and 27.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates

FORT LAUDERDALE, Fla., March 29, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

Motus GI Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

FORT LAUDERDALE, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and full year financial results on Tuesday, March 29, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Fourth Quarter and Full Year 2021 Results and Provide a Business Update on March 29

FORT LAUDERDALE, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in two upcoming investor conferences in March 2022.

Motus GI to Participate in Two Upcoming Investor Conferences in March 2022

BioDelivery Sciences

Kaival Brands Innovations Group

Check these penny stocks out for your watchlist today The post Trading Penny Stocks? Top Stock Market News for February 14th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 14th, 2022

-All New Pure-Vu EVS offers rapid set-up, improved navigation and enhanced cleansing capabilities to support expanded clinical utilization

Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System

Expanding patent portfolio extends first-mover advantage in the colonoscopy procedure market, estimated at close to 55M global procedures per year Expanding patent portfolio extends first-mover advantage in the colonoscopy procedure market, estimated at close to 55M global procedures per year

Motus GI Announces U.S. Patent For The Pure-Vu® System's Automatic Self-Purging Features

Motus GI Holdings' (MOTS) CEO Tim Moran on Q3 2021 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Motus GI Hldgs (NASDAQ:MOTS) is set to give its latest quarterly earnings report on Friday, 2021-11-12. Here's what investors need to know before the announcement.

Motus GI Hldgs Earnings Preview

Motus GI Holdings, Inc. (MOTS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

FORT LAUDERDALE, Fla., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its third quarter financial results on Friday, November 12, 2021, before the market open. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Third Quarter Results and Provide a Business Update on November 12

FORT LAUDERDALE, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company") announced with profound sadness that Samuel R. Nussbaum, MD, an independent director on the Company's board of directors, passed away on September 23, 2021. Dr. Nussbaum had proudly served on the Company's board of directors since 2016, where he was a member of the compensation, and nominating and corporate governance committees.

Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum

FORT LAUDERDALE, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that GastroZentrum Lippe, one of the top private endoscopy clinics in Germany, has enrolled patients into the European Union (EU) outpatient study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System. The study was initiated in mid-June 2021 with patients at the Radboud University Medical Center (Netherlands).

Motus GI Announces Enrollment of Patients at Second Site in the European Union Outpatient Study of the Pure-Vu® System

Motus GI Holdings' (MOTS) CEO Tim Moran on Q2 2021 Results - Earnings Call Transcript

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 9.09% and 20.48%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Motus GI Holdings, Inc. (MOTS) Reports Q2 Loss, Tops Revenue Estimates

FORT LAUDERDALE, Fla., July 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter financial results on Thursday, August 12, 2021, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Second Quarter Results and Provide a Business Update on August 12

FORT LAUDERDALE, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to present at the upcoming Ladenburg Thalmann Healthcare Conference begin held from July 13 to July 14.

Motus GI to Present at the Ladenburg Thalmann Healthcare Conference

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (Nasdaq: NK) and Immunity Bio, Inc. (Nasdaq: IBRX).

Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

FORT LAUDERDALE, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the publication of data from the REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study in an article titled, “A multicenter, prospective, inpatient feasibility study to evaluate the use of an intra ‑ colonoscopy cleansing device to optimize colon preparation in hospitalized patients: the REDUCE study” in the peer-reviewed journal BMC Gastroenterology. Among the important findings that the Company continues to emphasize since the data from the REDUCE study were first announced is the Pure-Vu system's 97% clinical success rate. The full publication can be found at (click here).

News for Motus GI Hlds Stock (MOTS)